Diabetes Care Drugs News

Related Pharmaceuticals Industry News

• February 2024: Alys Pharmaceuticals launched its research and development (R&D) immuno-dermatology-focused pipeline, backed by a USD 100 million financing from Medicxi.
• October 2023: Novartis received approval from the US Food and Drug Administration (FDA) for Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is one of the first FDA-approved fully human biologics that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.

• July 2022: Bavarian Nordic, the Danish company, expanded its production capacity to 10 million doses of the monkeypox vaccine.
• June 2022: Novo Nordisk A/S, a top global healthcare organization, and Echosens, a high-tech business providing liver diagnostic tools, partnered to promote early diagnosis of non-alcoholic steatohepatitis (NASH) and raise patient awareness.

• June 2024: Celltrion unveiled its positive phase III results for CT-P47, a biosimilar targeting RoActemra, in patients grappling with moderate-to-severe rheumatoid arthritis (RA).
• April 2024: Kiniksa Pharmaceutical Ltd unveiled findings from Cohort 4 of its Phase 2 clinical trial for abiprubart, targeting rheumatoid arthritis. Abiprubart, an investigational humanized anti-CD40 monoclonal antibody, aims to block the interaction between CD40 and its ligand, CD154.

• June 2024: Prime Therapeutics and Magellan Rx Management introduced a novel approach for locating pharmacies that dispense specialty drugs. Termed Pharmacy Match, this solution not only features an extended specialty pharmacy network but also enables real-time cost comparisons for drugs within the network.
• January 2023: TG Therapeutics Inc. reported the commercial launch of BRIUMVI (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis (RMS) while including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

• March 2024: Debiopharm announced the first patient dosed in the expansion of its open-label, non-randomized, multicenter Phase 1 study evaluating Debio 0123, an oral, potent, highly selective, and brain-penetrant WEE1 inhibitor, as a monotherapy in patients with recurrent or progressive solid tumors and gynecological cancers.
• January 2024: BioNTech SE and Duality Biologics (Suzhou) Co. Ltd revealed that the US Food and Drug Administration (FDA) gave Fast Track designation upon BNT325/DB-1305. This designation is aimed at expediting the development and review process for the treatment of patients diagnosed with platinum-resistant ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. These patients should have undergone one to three systemic treatment regimens prior.

• February 2024: The US Department of Health and Human Services (HHS) announced the launch of 2 grant programs through the Substance Abuse and Mental Health Services Administration (SAMHSA) to expand substance use disorder (SUD) treatment services.
• January 2023: Tempero Bio announced FDA clearance of an investigational new drug (IND) application for TMP-301. TMP-301 is an investigational metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) candidate that is intended for the treatment of cocaine use disorders (CUD).

• April 2024: The Food and Drug Administration approved Pfizer's Beqvez, a novel gene therapy designed for individuals with the less common "B" form of hemophilia.
• February 2023: The US Food and Drug Administration approved ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl]. It was previously referred to as efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement therapy. ALTUVIIIO is the first and only hemophilia A treatment that delivers normal to near-normal factor activity levels (over 40%) for most of the week with once-weekly dosing, significantly reducing bleeds compared to prior factor VIII prophylaxis.

• May 2024: Lexicon Pharmaceuticals Inc. chose Medidata, a Dassault Systèmes company, to propel its PROGRESS initiative. PROGRESS is a Phase 2b study of LX9211 aimed at treating diabetic peripheral neuropathic pain (DPNP). If successful, LX9211 could mark the first non-opioid drug approval for neuropathic pain in over two decades. By partnering with Medidata, Lexicon aims to expedite patient enrollment and streamline clinical trials for its AAK1 inhibitor, LX9211. This collaboration not only seeks to hasten the drug's development but also underscores a commitment to enhancing the overall patient journey, especially given the pressing need for effective chronic neuropathic pain treatments.
• February 2023: Anglo-French Drugs & Industries Ltd announced the release of a new product called AFD-NP to treat moderate to severe neuropathic pain.

• June 2024: Dr. Reddy's Laboratories Ltd inked a definitive deal with Haleon PLC to buy shares of Northstar Switzerland SARL, a subsidiary of Haleon. This acquisition focuses on Haleon's global portfolio of consumer healthcare brands in the nicotine replacement therapy ("NRT") category, excluding the United States. The portfolio includes Nicotinell, an over-the-counter brand in the NRT category, boasting a significant presence in more than 30 countries, including countries of Asia.
• January 2024: Daiichi Sankyo Healthcare planned to launch an OTC version of Calonal tablets (acetaminophen), an antipyretic analgesic from Ayumi Pharmaceutical, in Japan.

• February 2024: Tyber Medical LLC received clearance for the anatomical plating system in Canada. The comprehensive portfolio previously received FDA 510(k) approval in the United States and has now been cleared through Health Canada.
• January 2023: Zimmer Biomet acquired Embody Inc., a company that focuses on soft tissue healing. Through this acquisition, Zimmer Biomet strengthens its sports medicine portfolio.